Iambic Therapeutics, Inc

Iambic Therapeutics, Inc develops AI-driven platforms for drug discovery, combining physics-informed machine learning with high-throughput experimental automation to accelerate the design, synthesis and testing of novel medicines for serious diseases. Its work spans computational chemistry, protein structure and molecular interaction modelling, generative chemistry and target product profile optimisation. The company operates across the biotechnology, pharmaceuticals and oncology verticals.

At the core of the business is the Iambic Platform, an integrated system that links AI-guided design with automated experimentation. Two proprietary technologies sit within and alongside it: NeuralPLexer, used for molecular and protein structure and interaction modelling, and Enchant, a generative chemistry technology deployed in partnerships with pharmaceutical companies. According to the company, the platform has delivered drug candidates into human clinical trials with industry-leading speed across multiple target classes and mechanisms of action.

Iambic maintains an internal pipeline of potential best-in-class and first-in-class candidates. IAM1363, a HER2 inhibitor, is in Phase 1/1b studies. A selective dual CDK2/4 inhibitor for cancer indications and a programme focused on allosteric inhibition of KIF18A, targeting novel mechanisms of action, are also under way. In addition to its internal work, the company has entered strategic partnerships with pharmaceutical firms including Takeda and Lundbeck.